05/10/2009 (Agence Europe) - On Friday 2 October, the European Medicines Agency (EMEA) recommended that a third anti-flu A (N1H1) vaccine - Celvapan, an adjuvant-free vaccine produced by Baxter - be granted marketing authorisation. The formal decision to grant such an authorisation has to be taken by the European Commission. In its recommendation, the EMEA has included the same pharmacovigilance requirements as for the other two vaccines authorised a week ago. (O.J./transl.rt)